`
`LOTEMAXT“
`
`loteprednol etabonate
`ophthalmic suspension, 0.5%
`STERILE OPHTHALMIC SUSPENSION
`
`DESCRIPTION:
`
`LOTEMAXT“ (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-
`inflammatory corticosteroid for ophthalmic use. Loteprednol etabonate is a white to off-white
`powder.
`
`Loteprednol etabonate is represented by the following structural formula:
`
`ocuzet
`O
`
`Cal-l,,ClO,
`
`Moi. Wt. 466.96
`
`Chemical name: chloromethyl 17a-[(ethoxycarbonyl)oxy]-1lB-hydroxy-3-oxoandrosta-1,4-
`diene-l7B~carboxylate
`
`Each rnL contains: ACTIVE: Loteprednol Etabonate 5 mg (0.5%);
`INACTIVES: Edetate Disodiurn, Glycerin, Povidone, Purified Water and Tyloxapol.
`Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust the pH to 5.3-5.6. The
`suspension is essentially isotonic with a tonicity of 250 to 310 mOsrnol/kg.
`PRESERVATIVE ADDED: Benzalkonium Chloride 0.01%.
`
`CLINICAL PHARMACOLOGY:
`
`Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably
`delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte
`migratiori. Capillary proliferation. fibroblast proliferation, deposition of collagen, and scar
`formation associated with inflammation. There is no generally accepted explanation for the
`mechanism of action of ocular corticosteroids. However, corticosteroids are thought to
`act by the induction of phospholipase A, inhibitory proteins, collectively called lipocortins. It is
`postulated that these proteins control the biosynthesis of potent mediators of inflammation such
`as prostaglandins and leukotrienes by inhibiting the release of their common precursor
`arachidonic acid. AI‘5¢hid0ni¢ acid is fcleased fictn membrane phospholipids by phospholipase
`A,. Corticosteroids are capable of producing a rise in intraocular pressure.
`
`H:\R.A\7l l4\LOTEMAX\299pi.298.dOc
`
`Page l of 6
`
`Metrics EX1038, Page 1
` V
`
`Metrics EX1038, Page 1
`
`
`
`Loteprednol etabonate is structurally similar to other corticosteroids. However, the number 20
`position ketone group is absent.
`It is highly lipid soluble which enhances its penetration into
`cells. Loteprednol etabonate is synthesized through structural modifications of prednisolone-
`related compotmds so that it will undergo a predictable transformation to an inactive metabolite.
`Based upon in vivo and in virra preclinical rnetabolisn studies, loteprednol etabonate undergoes
`extensive metabolism to inactive carboxylic acid metabolites.
`
`'
`
`Results from a bioavailability study in normal volunteers established that plasma levels of
`loteprednol etabonate and A‘ cortienic acid etabonate (PI 91), its primary, inactive metabolite,
`were below the limit of quantitation (1 ng/mL) at all sampling times. The results were obtained
`following the ocular administration of one drop in each eye of 0.5% loteprednol etabonate 8
`times daily for 2 days or 4 times daily for 42 days. This study suggests that limited
`(<1 ng/ml) systemic absorption occurs with LOTEMAX.
`‘
`
`Clinical Studies:
`
`;
`
`flogtgggrgfle Inflammation: Placebo-controlled clinical studies donsuated that LOTEMAX
`is efiective for the treatment of anterior chamber inflammation as measured by cell and flare.
`
`Controlled clinical studies of patients with uveitis demonstrated that LOTEMAX was
`less effectivethan prcdnisolone acetate 1%. Overall, 72% of patients treated with LOTEMAX
`experienced resolution of anterior chamber cell by day 28, compared to 87% of patients treated
`with 1% prednisolone acetate. The incidence of patients with clinically significant increases in
`I01’ (210 mmHg) was 1% with LOTEMAX and 6% with 1% prednisolone acetate.
`
`Giant Eggjllg Qqgjflcrivitg: Placebo—controlled clinical studies demonstrated that LOTEMAX
`was effective in reducing the signs and symptoms of giant papillary conjunctivitis after 1 week of
`treatment and continuing for up to 6 weeks while on ueatment.
`
`gasonal Allergic Coniuncn‘viti,s;; A placebo-controlled clinical study demonstrated that
`LOTEMAX was efi‘ective in reducing the signs and symptoms of allergic conjunctivitis during
`peak periods of pollen exposure.
`
`INDICATIONS AND USAGE:
`
`LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the
`palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic
`conjunctivitis, acne rosacea, superficial punctate lteratitis, herpes zoster lreratitis, iritis, cyclitis,
`selected infective conjunctivitides, when the inherent hamrd of steroid use is accepted to obtain
`an advisable diminution in edema and inflammation.
`
`LOTEMAX is less efiective than prerlnisolone acetate 1% in two 28-day controlled clinical
`studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced
`resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone
`
`l>l:\RA\7l l4\LO'l'EMAX\299pi298.doc
`
`Page 2 of 6
`
`Metrics EX1038, Page 2
`
`Metrics EX1038, Page 2
`
`
`
`acetate 1%. The incidence of patients with clinically significant increases in IOP (2 10 mml-lg)
`was 1% with LOTEMAX and 6% withprednisolone acetate 1%. LOTEMAX should not be used
`in patients who require a more potent corticosteroid for this indication.
`
`LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular
`mrgery.
`
`.
`CONTRAINDICATIONS:
`LOTEMAX, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of
`the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis),
`vaceinia, and varicella, and also in mycobacterial infection ofthe eye and fungal diseases of
`ocular structures. LOTEMAX is also contraindicated in individuals with known or suspected
`hypersensitivity to any of the ingredits of this preparation and to other corticosteroids.
`
`WARNINGS:
`
`Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects
`in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Steroids
`should be used with caution in the presence of glaucoma.
`
`Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of
`secondary ocular infections. In those diseases causingthinning of the cornea or sclera,
`perforations_have been known to occur with the use of topical steroids. In acute purulent
`conditions of the eye, steroids may mask infection or enhance existing infection.
`
`Use of ocular steroids may prolong the course and may exacerbate the severity of many viral
`infections of the eye (including herpes simplex). Employment of a corticosteroid rnedicationin
`the treatment of patients with a history of herpes simplex requires great caution.
`
`The use of steroids after cataract surgery may delay healing and increase the incidence of bleb
`formation.
`
`PRECAUTIONS:
`
`General: For ophthalmic use only. The initial prescription and renewal of the medication order
`beyond 14 days should be made by a physician only afier examination of the patient with the aid
`ofmagnification, such as slit lamp biomicroscopy and, where appropriate, fluorescei_n
`If signs and symptoms fail to improve after two days, the patient should be re-evaluated.
`
`Ifthis product is used for 10 days or longer, intraocular pressure should be monitored even
`though it may be dificult in children and uncooperative patients (see WARNINGS).
`
`Fungal infections of the cornea are particularly prone to develop coincidentally with long-term
`local steroid application. Fungus invasion must be considered in any persistent corneal
`ulceration where a steroid has been used or is in use. Fungal cultures should be taken when
`appropriate.
`
`I-I:\RA\7l l4\LOTEM.AX\299pi29I.do¢
`
`Page 3 of6
`
`Metrics EX1038, Page 3 '
`
`Metrics EX1038, Page 3
`
`
`
`Information for Patients: Patients should be advised not to allow the dropper tip to touch any
`surface, as this may contaminate the suspension. Ifpain develops, redness, itching or
`inflammation becomes aggravated, the patient should be advised to consult a physician As with
`all ophthalmic preparations containing benzalkonium chloride, patients should be advised not to
`wear sofi contact lenses when using LOTEMAX“.
`
`Carcinogenesis, mutagenesis, impairment of fertility: Long-term animal studies have not been
`conducted to evaluate the carcinogenic potential ofloteprednol etabonate. Loteprednol etabonate
`was not genotoxic in the Ames test, the mouse lymphoma tk assay, or in a chromosome
`aberration test in human lymphocytes, three in vitro tests. In vivo evidence of genotoxicity, an
`increased frequency of micronucleated immature erythrocytes, was not observed in mice that
`received a single 4 gm/kg dose of loteprednol etabonate (50,000 times the maximum daily
`clinical dose). Treatment of male and female rats with up to 50 mg/kg/day and 25 mg/kg/day of
`loteprednol etabonate, respectively, (600 and 300 times the maximum clinical dose, respectively)
`prior to and during mating did not impair fertility in either gender.
`
`Pregnancy: Teratogenic efiects: Pregnancy Category C. Loteprednol etabonate ha been shown
`to be embryotoxic (delayed ossification) and tn-atogenic (increased incidence of meningocele,
`abnormal lefi common carotid artery, and limb flexures) when administered orally to rabbits
`during organogenesis at a dose of 3 mg/kyday (35 times the maximum daily clinical dose), a
`dose which caused no maternal toxicity; the no-observed-effect-level (NOEL) for these effects
`was 0.5 mgilcg/day (6 times the maximum daily clinical dose). Oral treatment ofrats during
`organogenesis with 50 or_ 100 mg/kg/day (600 and 1,200 times the maximum clinical dose)
`resulted in embryotoxicity (increased post-implantation losses with 100 mg/kg/day, and
`decreased fetal body weight and skeletal ossification with 50 and 100 mylrg/day); doses of 5 (60
`times the maximum daily clinical dose), 50 and 100 mg/kg/day caused teratogenicity (absent
`innominate artery at all doses, and cleft palate and umbilical hernia at 50 and 100 mg/kg/day).
`Loteprednol etabonate was maternally toxic (significantly reduced body weight gain during
`treatment) when administered to pregnant rats during organogenesis at doses of 5 to 100
`mg/kg/day but not at 0.5 mg/kg/day. The NOELS for the embryotoxic and teratogenic efiects in
`rats were 5 mg/kg/day and 0.5 mg/kg/day (60 and 6 times the maximrnn daily clinical dose) for
`embryotoxicity and teratogenicity, respectively.
`
`Oral exposure of pregnant rats to 5 and S0 mg/kyday of loteprednol etabonate during the fetal
`period, a maternally toxic treatment regimen (significantly decreased body weight gain), resulted
`in teratogenicity (umbilical herniation) and bryotoxicity (decreased fetal birth weight); the
`NOEL for these effects was 0.5 mg/kyday. Oral exposure of female rats to 50 mg/kg/day of
`loteprednol etabonate from the start of the fetal period through the end of lactation, a maternally
`toxic treatment regimen (significantly decreased body weight gain), gave rise to decreased
`growth and survival, and retarded development in the offspring during lactation; the NOEL for
`these effects was 5 mg/kg/day. Loteprednol etabonate had no eflect on the duration of gestation
`or parturition when administered orally to pregnant rats at doses up to 50 mg/kg/day during the
`fetal period.
`'
`
`H:\RA\7l l4\LOTEMAX\299pQ98.doc
`
`Pue 4 of 6
`
`Metrics EX1038, Page 4
`
`Metrics EX1038, Page 4
`
`
`
`Oral treatment of female rats with 25 mg/kg/day (300 times the maximum daily clinical dose)
`from prior to mating through parturition increased the duration of gestation.
`
`Nursing Mothers: It is not known whether topical ophthalmic administration of corticosteroids
`could result in sufieient systemic absorption to produce detectable quantities in human milk.
`Systemic steroids appear in human milk and could suppress growth, interfere with endogenous
`corticosteroid production, or cause other untoward efieets. Caution should be exercised when
`LOTEMAX is administered to a musing woman.
`
`Pediatric Use: Safety and efiectiveness in pediatric patients have not been established.
`
`ADVERSE REACTIONS:
`
`Reactions associated with ophthalmic steroids include elevated intraocular pressure, which may
`be associated with optic nervedamage, visual acuity and field defects, posterior subcapsular
`cataract formation, secondary ocular infection from pathogens including herpes simplex, and
`perforation ofthe globe where there is thinning ofthe cornea or sclera.
`
`Ocular adverse reactiom occurring in 5-15% of patients treated with loteprednol etabonate
`ophthalmic suspension (0.2%-0.5%) in clinical studies included abnormal vision/blurring,
`burning on instillation, ehemosis, discharge, dry eyes, epiphora, foreign body sensation, itching,
`injection, and photophobia. Other ocular adverse reactions occurring in less than 5% of patients
`include conjunctivitis, corneal abnormalities, eyelid erytherna, keratoconjunctivitis, ocular
`irritation/pain/discomfort, papillae, and uveitis. Some of these events were similar to the
`underlying ocular disease being studied.
`
`Non-ocular adverse reactions occurred in less than 15% of patients. These include headache,
`rhinitis and pharyngitis.
`
`In controlled, randomized studies of individuals treated for 28 days or longer with loteprednol
`etahonate, the incidence of significant elevation of intraocular pressure (2 10 mm Hg) was 2%
`(15/901) among patients receiving loteprednol etabonate, 7% (11/164) among patients receiving
`1% prednisolone acetate and 0.5% (3/5 83) among patients receiving placebo.
`
`DOSAGE AND ADMINISTRATION:
`SHAKE VIGOROUSLY BEFORE USING.
`
` Apply one to two drops of LOTEMAX into the
`conjunctiva! sac of the affected eye(s) four times daily. During the initial treatment within the
`firstweelr, the dosing may be increased, up to 1 drop every hour, ifnecessary. Care should be
`taken not to discontinue therapy prematurely. If sips and symptoms fail to improve afier two
`days, the patient should be re-evaluated (See PRECAUTIONS).
`
`H:\RA\71l4\LOTEMAX\299pi298.doc
`
`Page 5 of 6
`
`Metrics EX1038, Page 5
`
`Metrics EX1038, Page 5
`
`
`
` @ply one to two drops ofLOTEMAX into the conjunctiva! sac
`ofthe operated eye(s) four times daily beginning 24 hours afier surgery and continuing
`throughout the first 2 weeks of the postoperative period.
`
`_
`HOW SUPPLIED:
`LOTEMAX” (loteprednol etabonnte ophthalmic suspension) is supplied in a plastic bottle with
`a controlled drop tip in the following sizes:
`2.5 mL (NDC 24208-299-25) s AB29904
`5 mL (NDC 24208-299-05) - AB29907
`10 mL (NDC 24208-299-10) - AB29909
`15 mL (NDC 24208-299-15) - AB299ll
`
`DO NOT USE IF NECKBAND IMPRINTED WITH “Protective Seal” and yellow (mortar
`and pestle graphic) IS NOT INTACT.
`
`-
`
`Storage: Store upright between 15° - 25°C (59° - 77°F). DO NOT FREEZE.
`
`KEEP OUT OF REACH OF CHILDREN.
`
`Rx only
`
`Manufactured by:
`Bausch & Lamb Phaxmaceuticals, Inc., Tampa, Florida 33637
`under Agreement with Pharmos Corporation.
`'
`U.S. Patent No. 4,996,335
`US. Patent No. 5,540,930
`0 Bausch & Lamb Pharmaceuticals, Inc.
`
`XO503l7 (Folded)
`XMl0O39 (Flat)
`Rev. 2/98-8B
`
`’ H:\RA\71l4\LO'l'EMA.X\299pi.298.doc
`
`Pnge 6 of6
`
`Metrics EX1038, Page 6
`
`Metrics EX1038, Page 6
`
`
`
` ,
`
`*¢e.b9~4,‘/99?
`
`unmann:~AcM-
`suunauuu
`5:-
`5w_-_v.~:,..‘"'*~«»e»:.*:.'*‘*
`-»'""-"-'s=‘._-.=,
`3 usun!/~
`.
`~ Nhniufillttllnro
`g “"""
`e-_r,»,«wm Lztemax I'.::*.:.*:.'.'"::-.'::.:*=r :
`fiduadiuirsquufli mnrmumcusuuv.
`“mg”;
`AH hmllm
`flmi
`anvm‘
`Hu:—u1n1uuFI.!m7
`at);-m-on-aura:
`
`
`
`myscn
`
`CORE 29904 LABEL
`4/C: PMS 197, PMS Violet, Cyan. Black
`DIMENSIONS: 3 1/8" x 13/16"
`3/4" unvamish area at left
`
`L-1605
`ART us AT 100%
`PHARMACODEf682
`
`_
`,
`_
`i'i5’P5»1f‘.3 1 F513 ‘JAY
`O
`3! is
`
` Metrics EX1038, Page 7
`
`Metrics EX1038, Page 7
`
`
`
`CORE 29995 SAMPLE LABEL
`4/C: PMS 197. PMS Violet, Cyan, Black
`DIMENSIONS: 3 1/8" x 13/16"
`3/4" unvamish area at left
`L-1 605
`ART IS AT 100%
`PHARMACODE#683
`
`Iv\l’§C|l
`I l.0M B '
`I05 NS‘-I”-$6
`
`zilvlil-Ii-viiiiw-«ti!
`' SIQIWMTINICSSDQI
`2.5 ml
`sunsnruuu
`
`I$dZMH:lC1'K
`M
`gmdivnusqlilt
`........‘:.u“'..."Pm
`DIIUIMIIIHCIIAID
`$1!!!
`Ilfluttwniul‘
`LCIILIK SHYHILU
`Fflfiflflflflfiml
`AH Iyhnflld
`M-utuxluuflnll
`rip-unnruulu
`
`APPEARS nus WAY
`on ORIGINAL
`
`Metrics EX1038, Page 8
`
`Metrics EX1038, Page 8
`
`
`
`[||Ԥ(j"
`-I WMH’
`'05-
`
`Mali. umuut ACNE
`as
`.nf1:%"""‘“'
`Iuuunnolumnv.
`I. ‘V U‘ U IKIJW
`1%!“ I
`Pvfitlnl 5054'
`
`upufiugummu
`xtaummuulzsnoaou
`5 ml
`
`“iii-MI-II
`=I—nAk mag:
`
`_
`
`lllllllll
`
`CORE 29907 LABEL
`4/C: PMS 197. PMS Violet, Cyan, Black
`DIMENSIONS: 3 1/8" x 13/16"
`3/4” unvamish area at left
`L-1605
`ART IS AT 100%
`PHARMACODE#681
`
`APPEARS THIS WAY
`ON ORIGINAL ‘
`
`Metrics EX1038, Page 9
`
`Metrics EX1038, Page 9
`
`
`
`unnnamnvum:
`
`MILSCII
`
`Sumo: an
`8-
`I-L
`Inn!‘
`NEWER
`Inn
`
`TH?
`
`uDC‘Zl-1.2)?-gs;-In
`
`_
`bIHdn&qcnulfl
`_ slaummvunanamu
`Will.
`
`00 I91 N I Cfillllt
`I nun-vein-
`XII‘!!!
`Buov mun
`Ill VILLDW
`uuul-Mun
`knjI1k.|aIuFl.E1
`utlquclu-any-ICII
`
`UIIIIIIMIQGI
`
`DORE 29909 LABEL
`
`4/C: PMS 197, PMS Violet, Cyan. Black
`DIMENSIONS: 3 3/8" x 0.711"
`5/8" unvarnish area at left
`L-1614
`ART IS AT 100%
`PHARMACODE#680
`
`APPEARS nus WAY
`ON OREGINAL
`
`Metrics EX1038, Page 10
`
`Metrics EX1038, Page 10
`
`
`
`l\l’SlIll
`E U)!!! '
`NDC IQWES9 '5
`
`hgaaéanuuummasi
`SIEIMMIMAKQUBQI
`
`I5 IIL
`
`llfldflflflt:
`EYM.-tnuutdiuuuu
`
`III
`m"-°.':.""....**.::
`nun-nmmn
`'
`W’:-'::'17amu
`an-an-n as «man
`In nmnm
`«-uu naou'u':m'.'nn-uh.
`htunflunllli
`
`roam-ax-u’
`|
`Mnnvnulnonuo
`5 WV WHEY
`-..::____
`lunuun
`
`Ihimllh hnutd
`humanism:
`
`&iLIi~:&Lh'.
`IrK3¥‘I'I—:-‘fl-—I
`
`IIIIICIIEIIIM
`
`Illlllill
`
`I
`
`CORE 29911
`
`4/C: PMS 197, PMS Violet. Cyan. Black
`DIMENSIONS: 3 3/8" x 1 3/8" 5/8" Non uv @ left
`L-1604
`ART IS AT 100% -
`PHARMACODE#992
`
`APPEARS THIS WAY
`ON ORIGINAL
`
` Metrics EX1038, Page 11
`
`Metrics EX1038, Page 11
`
`
`
`Sllile Qmhllllfli
`s“’"'“°"
`
`-
`
`,
`-
`3
`
`i
`‘
`
`___.__'
` :
`S .
`S 3
`E?
`E ’
`S g 5
`S ;
`‘ "‘
`
`I
`I
`I
`
`mason
`X09123!
`I1/I-Q
`
`
`A
`
`*
`
`’
`
`I Locuu beau-uzssoc/as 2/2:/as 12:0: PI! ngc 1
`
`$
`
`muscn
`& LOM B ‘
`no: 243:; 2:»; as
`
`.
`V
`.
`'
`=bq:a&dui:unouédxsqa:nnII5%
`’
`,
`'
`‘
`"‘‘“"'""""’
`
`
`
`I E‘:$£u-LcourAns-
`rononmutmc
`'
`‘
`USE OM-V3
`2:303:Em°""'
`‘
`pucnygf
`I KEP U17 OF
`Ednuuo Divan. Glvetn. Masons.
`; EACH U5
`| Mandi"
`" Sim‘ 1
`MMWytekgugg/bmol.
`I CHLIRBII.
`Hv-tn-in
`hunumnanjmnhn - S,
`.
`on to 5.3-5.?¥M amunsm as
`"'9'?
`csmmw mum with a uncicy aI
`3"" WV“
`250 In 3IIm0:nuI/
`balm-n
`PIEEIVATNE
`6‘-25‘C I59‘-77°F).
`auuanmnuuuinnomx
`DONCIT FREEZE
`
`;
`;
`
`no not us:
`an,“ mu“
`amoonun.
`IF necxamn
`_
`SHAKE VIHIMJSU
`mpnmfip wmg
`
`. W°'*i"*'“‘~
`"Pnuclivl sea:
`~ mm,
`AND YELLOW
`
`i
`5,.,,,,.'§,"f,',,‘}:'
`Is not mun.
`-«-=~»:=-«»~=
`
`E Yam. nurgmaaszv am:
`am 3‘ "W
`
`
`I us.Pum uu.sss.3as
`us. Pam! Na 5.540.930
`Ofiual I Lam Pnuun-mats. hr.
`
`
`
`
`I
`
`g—» I
`
`I
`
`\
`
`//I
`
`/
`
`Emir: carton is caaied with vamish cxapt bottom
`flap M anon.
`CORE 29904
`IIC: PMS 197, PMS Violet, win. Black
`DIMENSIONS: 1 SIB" H 1/16‘ x 3 3/8"
`L-2004
`ART IS AT 100%
`PHARMACODEIZMS
`SCANNER BAR POSITION: 2.4375" (39)
`
`I
`1’,
`
`APPEARS THIS WAY
`
`ON ORIGINAL
`
`Metrics EX1038, Page 12
`
`Metrics EX1038, Page 12
`
`
`
`Lotunx bnxus-AS29900/95
`
`2/24/9| 12:10 HI
`
`P390 3
`
`$
`
`I /
`
`lllllllllll
`
`uuwaasng xmguuudo &[u as
`
`
`
`.:4;.u~
`
`EACH nl. CUITMHS:
`ACYNE
`ummmol Emmm
`5
`IQSN:
`TIES:
`Emma Dnulium Gyeuin. Pnvihrn.
`Rlilild Wat! Id Tyloxapol
`Nytndmbvi: Add um/or Sodom
`
`FOR OPHTNAIJMC
`USE l|NlV.
`
`KEH’DUT(F
`‘REM?-ICF
`Ct-IDREN
`
`BAIESCH
`& Low:
`woc .u.a-29»-gt
`
`V
`Cos:
`
`
`
`1
`.1::E€’I'£!.>& %
`5”‘.“mum:
`
`Rllflfl
`
`_£—#.U! NIH FL‘.-»..
`
`Sloan:
`Sm: uprigm
`botween
`S‘-ZS'C 69'-T7'F).
`DC! MD! FREZE
`on NOT use
`nr uscxnmo
`mmmrm wrm
`
`
`'Pm\¢c1iv| Sal‘
`mo vmow 5
`
`
`Is NOT mun.
`
`
`
`
`
`pH on 515; In amnion is _
`Hydmm awn man m aim in
`cmnubly ‘min: with 3 Innicny at
`250 to :10 win
`PIESEIVATM
`.
`Blmhnim Ohm 0.01 ‘I;
`usmu MIMIE:
`SuPouIumIuuL
`SHAKE VHHIUSIV
`BEFORE USI6.
`Mmufaeund by
`Busch A Lunb
`Fvamnunrls. hc
`Tina, Fluih 3337 mot
`( wilh mums Cwnomim
`us. Pam No. 0,996,335
`US. Pawn Nu. 5540.333
`unusual. LnuRmIa:ancal.I.he.
`
`
`
`Enun canon is coma with vambsh
`Ixcwt bottom flap at anon.
`CORE 29995
`4/C: PMS 197, PMS Viobt. cyan. Blast
`DIMENSIONS: 1 5/8‘ X1 1/16' x 3 3/3"
`L-2004
`ART IS AT 100%
`PHARMACODERMG
`scmuen am POSlTlON: 3- (43)
`
`lllllllllll
`
`APPEARS THIS WAY
`ON ORiGlNAL
`
`Metrics EX1038, Page 13
`
`Metrics EX1038, Page 13
`
`
`
`| Lotenlx boaml-A329907I09/11
`
`1/24/90 12:00 HI
`
`Page 1
`
`$
`
`,
`
`If
`
`> //
`
`.
`
`K
`
`L}temax
`-II-I-I-3 I
`sum Onhmavnc
`‘
`s“‘°""°"
`-
`*
`
`;
`
`°
`
`
`
`0
`:
`3 ‘
`§
`26
`N
`=
`: .-.
`
`M2937
`‘,
`XOSE
`‘_
`12/53-H ‘
`‘\
`\.._._.__
`
`BAUSCH
`“fie
`
`I
`3
`
`%
`
`A
`
`%
`
`.....
`"
`
`.
`
`.
`.
`
`-
`
`,
`
`- ..
`
`
`
`
`
`
`,‘
`I
`/
`\
`..._____n
`
`1
`‘
`
`‘
`rm onfiluuuc
`ggxrzlavau. momma
`USE ON”.
`Lnlqnttnlflnhuule
`my auto;
`5
`REACHOF
`Edgxgle (Indium Glyurh. Poimne.
`:‘,'.::..."*':.:“.L'::~°u..... W‘
`nmnmgmugagggggsgmg
`sun”:
`stuglufwn
`usumitymun:mm: tummy ol
`' him!"
`250 In 3D IIIOWIOII
`1 S‘-25‘C(5§‘-77°FL
`HESERVATNE
`BIn1zoI:mimDIlub:nm5k
`, nouor msszg
`USUM. DOSAGE-
`OO NM USE
`
`8" P"“°' "M
`if uicnuuo
`SHAKE VENOUS“
`IIPRINTED WITH
`
`‘
`AND YELLOW
`_
`3
`ICFOIE USING.
`‘Pmluciivl Sn;
`
`,’’‘'''',_,,'§''l'q'}'},,”'
`IS NOT mun.
`
`hum.
`mm
`3, on"
`
`can
`.
`,
`az.:."~'.z:~.",:':3°:=~°~°"~
`
`"'5:P“-I:::"sw’gn>
`K
`Skmlu Uphlmlmzc Suspvruson
`
`_
`,v
`'
`
`
`
`
`
`Entire canon is coated with varnish except bonorn
`the or anon.
`CORE 29907
`IIC: PMS 197. PMS Vvolel, Cyan. Black
`DIMENSIONS: 1 518' X 1 1/16‘ X 3 3/3"
`L-2004
`ART IS AT 100%
`PHARMACDDEIZSOO
`SCANNER BAR POSITION: 0.25‘ (4) 5 2.25‘ (36)
`
`AWEARS THiS WAY
`
`ON OREGINAL
`
`Metrics EX1038, Page 14
`
`Metrics EX1038, Page 14
`
`
`
` Lacuna: bonus-AI299|)'ll09I11
`
`2/2!/9! 12:02 HI Pay: 2
`
`$
`
`lllllllllll
`
`\
`
`unsuadsng mugeqmflo omens
`. -
`.2
`_
`.
`«
`‘
`
`‘ I
`
`,‘
`J:
`
`-
`
`.'
`
`/"
`
`I‘
`‘\
`\\
`l
`
`/
`
`4;‘
`
`/I
`
`3
`
`=.
`
`j
`
`‘
`
`-
`
`5
`
`?.'é8i’.I"I"“‘”‘°
`'
`’: KEEP an or
`: WW“
`CHLUIEN
`
`2‘”S°"-
`“Dc .,
`
`Lztemax
`uunmvnumuuil
`Sm-Ie Dohusamu:
`
`5
`.
`[
`-
`I
`i
`;
`3
`L
`;
`' I
` > ;
`'=='%____. -7 =
` Ef
`I
`__:..:L
`*'.__-_°.-._:— N V
`I ,1 T =
`, ,,
`
`.
`
`St:*I:|c Uphlhrsfml: Sazptmrxnn
`
`
`\
`\
`
`’
`
`.
`
`
`
`Emir: canon is coalui with varnish uccol bottom
`Ilap ul canon.
`CORE 29909
`AIC: PMS 197, PMS Violet, Cyan. Black
`DIMENSIONS: 1 5/8" X 1 1/16" x 3 3/3”
`I.-2004
`ART IS AT 100%
`PHARMACODEIZSOI
`SCANNER BAR POSITION: 0.25" (4) & 1.25" (20)
`
`Illllllllll /
`
`A?‘PE..51F3S WES WAY
`05% ORISIIIAL
`
`Metrics EX1038, Page 15
`
`I
`
`2
`
`_
`
`\
`
`.
`t
`
`.
`
`i€:‘r‘3e'«‘°°'"""‘=
`I.n(uo¢IoIEubuu(c
`;",g;2‘~2;f-
`£d:t:uDus:dilILGIvcIn,Pov‘daIe,
`hlilbd Wald aid Iytoxapot
`wtocfllcric Aaanam snag»
`Hwrnndn
`bnddd to qua the
`#4 In 5,3-&_& In anpiuon I:_
`%la;g -scion?/mm runway ol
`mesawmvs Anna
`auuatumcmuaunnnus
`mun uosme
`s-we--«
`‘
`SNAKE VIGDIDUSLV
`IEFOIEUSING.
`;
`I M'”‘;"f:;’V
`°”°‘».mm....\..
`I
`V-mFw_-mu-is
`Mum! wuh Prunm: Cwpamm =
`uS.PmmNn.4.9ss.J3s
`’
`fluId\luI'rbFIIrv3In'liI.h:
`us‘ Pu.“ Nu‘ isuum
`—
`
`sun”;
`5"“ “run
`hem".
`E‘-25'C I59‘‘77'FI-
`DONOTFREEZE
`
`£223.22:
`IMPRINTED WITH
`"PIIICCIIVI Sui‘
`mo veuuw
`IS NOT mum.
`
`
`
`I
`
`Metrics EX1038, Page 15
`
`
`
`‘ Lotlllx boxu-AIZBSOTIDD/11
`
`2/14/90 12:00 Pll
`
`Page J
`
`$
`
`YT,
`
`\\V
`
`K
`
`,":—_‘-‘.
`
`/
`
`/V
`
`!
`
`'!
`
`\.
`lllllllllll
` mgsumms znmpqnpg apmg
`
`
`
`
`Ll <v.:&J >
`
`.
`
`._
`N.
`I
`I
`/
`
`$‘r~:""”°'"""*
`Lolcuutnfildaunaxc
`5
`$;,'§§f-
`Ednuulisufim Glvur'I1.PmndntI.
`mar-u wuumwnnaot
`I Hyctodduicldduua/«Snail»
`1 Mmmbomdtp-Qxstm Sturggg:
`;
`game 515;. ThuVmq.aeum|_s_
`5"" WV.‘
`lo
`ammo:
`guluoaglI0(IlI\:;lhl Iuuuty n!
`hm!”
`HESERVATWE AGED.
`T5‘-ZS‘C I55‘-77'fl_.
`auuuknnmuu mom
`IXJNOT FREEZE
`‘
`usuu nouns;
`s--'-=~»-~-I-
`SHAKE vuaanousu
`IEFORE IISIIG.
`Man:
`an
`hm';“[m"'
`«—=-=~~=
`V
`g Tllnl. 3337mm‘
`Agnnuuwnhhunnos Corpumom
`us.PmmNn.4.99s.33s
`Us P'w“w 55$!”
`eau.ma.Lanmanuuucus.u
`
`:
`
`.E3£‘ciL%i%
`mmmm wrm
`AND vmow
`Ttouetivo Sn‘
`ts NOT mucr.
`II; guy
`
`1
`
`«
`
`:
`
`’
`
`
`
`C
`
`'
`xssraur ov
`“EACHOF
`CHIJREN.
`
`“C u:._;_:_,’ '5
`
`Lztemax V
`
`snug:Ovhlhfink
`‘mm
`
`-
`
`_
`_
`uhpadduimgaqifixnqumflfi
`_
`“ __ H
`‘_
`._ -.
`‘
`.,_:-
`--
`-
`-
`,, A
`-
`‘
`
`.
`"
`
`'
`
`
`
`Slenlrg 0p?11h3lm'L $uS;1m=.m
`
`_______-
`'
`—-T "'
` m
`2
`‘i=3... '
`T. 3 V
`iv
`3
`T N 1
`L g ;
`I _
`!
`
`,
`\
`T
`\
`
`mam
`xnsusv
`Imam
`
`I
`'
`
`.
`
`'
`
`I’
`,
`,
`I
`
`.\
`
`Emir: anon is tuned with varnish except bottom
`nap of canon.
`
`CORE 29911
`UC: PMS ‘I97, PMS Violet, D/an. Black
`DIMENSIONS: 1 5/!" x1 1/16” x 3 3/3'
`L-2004
`ART IS AT 100%
`PHAHMACODEIZSDZ
`SCANNER BAR POSITION: 0.25‘ (4) 3 1.75‘ (28)
`
`
`
`'5
`;'‘g-.?.
`''f-'
`I‘ U|§Iui
`
`
`7-! I.
`iii‘: L
`
`Metrics EX1038, Page 16
`
`Metrics EX1038, Page 16